Zosano Pharma : Corporate Presentation July 2021

Corporate Presentation

July 2021

Copyright © 2021 Zosano Pharma Inc. | Confidential

1

Forward-Looking Statements

This presentation contains forward-looking statements regarding Zosano's technology and product candidates, including M207, Zosano's plans for and the anticipated timing with respect to the commencement of the PK study and the availability of data from the study, the expected timing of the resubmission of the M207 NDA to the FDA, the potential benefits and availability of M207 for patients, and other future events and expectations.

Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict, and actual outcomes may differ materially. These include, without limitation, risks and uncertainties associated with the process of discovering, developing and commercializing products that are safe and effective for use as human therapeutics, risks inherent in the effort to build a business around such products and other risks and uncertainties described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K and its periodic reports filed with the Securities and Exchange Commission. Although Zosano believes that the expectations reflected in these forward-looking statements are reasonable, we cannot in any way guarantee that the future results, level of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. All forward-looking statements are based on information currently available to Zosano and Zosano assumes no obligation to update any such forward-looking statements.

Copyright © 2021 Zosano Pharma Inc. | Confidential

2

Zosano Pharma: Working to Transform How Drugs Are Delivered

Differentiated

Technology

Significant

Clinical

Evidence

Versatile

Platform

OUR MISSION

Advancing Patient Care and Transforming

Patient Lives Through Therapies Developed

Utilizing Our Proprietary Delivery Platform

OUR FOCUS

Late Stage Clinical Development Program for the Acute Treatment of Migraine Where Current Therapies Have Significant Limitations

OUR FUTURE

Patch Technology Designed to Allow for Innovative Application of Proteins, Peptides and Vaccines

Copyright © 2021 Zosano Pharma Inc. | Confidential

3

Executive Summary and Recent Developments

	Transformative	▪ Technology (formerly MACROFLUX) Developed at ALZA Corp/J&J
	▪ 26 Patent Families and IP Protection
	Delivery Platform	▪ First and Only Microneedle Patch to be Included in an NDA Submission to the
		FDA
	Addressing	▪ Migraine is Ranked Globally as the Seventh Most Disabling Disease1
	▪ Migraine Impacts approximately 37 Million People in the US2
	Significant Unmet
	▪ M207, if Approved, May Have the Potential to Offer Fast, Complete and a
	Needs in Migraine
	Durability of Effect to Patients Suffering From Migraine3
		▪ Mitsubishi Tanabe Feasibility Study Agreement in August 2020
	Partnerships	▪ Two Additional Feasibility Studies Signed with Undisclosed Partners in Q4 2020
	▪ Actively Seeking Collaborations that Utilize our Proprietary Transdermal
		Microneedle Patch Technology
		▪ Initiated Pharmacokinetic (PK) Study in June 2021 to Support Resubmission of the
	Key Developments	M207 NDA
	▪ Eversana Commercialization Partnership - Commercial Services Valued at
		Approximately $250MM Over 5 Years, if M207 is Approved

1. Steiner TJ et al. Migraine: the seventh disabler. The Journal of Headache and Pain 2013, 14:1. 2. American Migraine Foundation (2019) Migraine Essentials: What It's Like Living with Migraine. Retrieved from https://americanmigrainefoundation.org/living -with-migraine/migraine-essentials. 3. Spierings ELH et al. Randomized, double-blind,placebo-controlled,parallel-group,multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine. Cephalalgia 2018 Feb;38(2):215-224.

4

Zosano's Transdermal Drug Delivery

Novel & Proprietary

Transdermal patch with drug-coated microneedle array

Designed to be Rapid & Consistent

Designed for rapid and consistent absorption of drugs into capillary bed

Designed to Minimize Application Site Sensation

Shallow penetration designed to minimize stimulation of nerve endings

Convenient & Discreet

Quarter size patch with nickel sized array (~2,000 microneedles)

Designed to be Easy to Use

Substantial patient experience in clinical trials

Copyright © 2021 Zosano Pharma Inc. | Confidential

5